Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
ConclusionsMebendazole may be an effective alternative treatment of G. duodenalis infections in both children and adults. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - December 12, 2018 Category: Drugs & Pharmacology Source Type: research
Effectiveness and tolerability of 3 day mebendazole treatment of Giardia duodenalis infections in adults and children: two prospective, open-label Phase IV trials
ConclusionsMBZ may be an effective alternative treatment of G. duodenalis infections in both children and adults. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - December 1, 2018 Category: Drugs & Pharmacology Source Type: research
Evolution of Dihydropyrimidine Dehydrogenase Diagnostic Testing in a Single Center during an 8-Year Period of Time
ConclusionsPrevious studies have shown that DPD status should be determined before treatment with fluoropyrimidine agents to prevent unnecessary side effects with possible fatal consequences. Our study in combination with literature shows that there is a discrepancy between the DPD enzyme activity and the presence of clinically relevant single nucleotide polymorphisms. At this moment, a combination of a genetic and enzyme test is preferable for diagnostic testing. (Curr Ther Res Clin Exp. 2018; 79:XXX–XXX). (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - November 27, 2018 Category: Drugs & Pharmacology Source Type: research
Special Meeting Report: Keystone Symposia on Molecular and Cellular Biology, Hannover, Germany, June 4-8, 2018
Publication date: Available online 14 November 2018Source: Current Therapeutic ResearchAuthor(s): Philip D. Walson (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - November 15, 2018 Category: Drugs & Pharmacology Source Type: research
Evolution of dihydropyrimidine dehydrogenase diagnostics in a single center in a time-period of eight years
Publication date: Available online 31 October 2018Source: Current Therapeutic ResearchAuthor(s): Marieke J.H. Coenen, Aimée D.C. Paulussen, Marc Breuer, Martijn Lindhout, Demis C.J. Tserpelis, Anja Steyls, Jörgen Bierau, Bianca J.C. van den BoschAbstractPurposeFluoropyrimidine treatment can be optimized based on DPD (dihydropyrimidine dehydrogenase) activity. DPD dysfunction leads to an increased exposure to active metabolites, which can result in severe or even fatal toxicity.MethodsWe provide an overview of eight years DPD diagnostics (n=1194).ResultsWithin the study period our diagnostic test has evolved from a single...
Source: Current Therapeutic Research - October 31, 2018 Category: Drugs & Pharmacology Source Type: research
PORTEX® North Polar tube reduces the risk of epistaxis during nasotracheal intubation: A prospective, randomized clinical trial
ConclusionsWe conclude that the PORTEX® North Polar tube was associated with less epistaxis and manipulations such as laryngeal compression and head position changes when compared with the spiral tube during NTI. The velvet soft PVC material of NPT appears to be responsible for this advantage.Graphical abstract (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - October 9, 2018 Category: Drugs & Pharmacology Source Type: research
Intensification of basal insulin therapy with Lixisenatide in patients with type 2 diabetes in a real-world setting: the BASAL-LIXI Study
Publication date: Available online 9 October 2018Source: Current Therapeutic ResearchAuthor(s): Diego Bellido, Pablo Abellán, José Manuel Ruiz Palomar, Rogelio Álvarez Sintes, Andreu Nubiola, Virginia Bellido, Gracia Romero, Basal Lixi Study investigatorsABSTRACTPurposeBasal insulin reduces fasting blood glucose (FBG), but postprandial blood glucose (PPG) may remain higher. Traditional strategies with rapid insulin intensification can cause hypoglycemic episodes and weight gain. Glucagon-like peptide-1 receptor agonists, such as the short-acting lixisenatide, are able to control postprandial excursions, without weight g...
Source: Current Therapeutic Research - October 9, 2018 Category: Drugs & Pharmacology Source Type: research
Antipsychotic Drug Dispensations in Older Adults, Including Continuation After a Fall-Related Hospitalization: Identifying Adherence to Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions Criteria Using the Nova Scotia Seniors' Pharmacare Program and Canadian Institute for Health's Discharge Databases
Publication date: 2018Source: Current Therapeutic Research, Volume 89Author(s): Shanna C. Trenaman, Barbara J. Hill-Taylor, Kara J. Matheson, David M. Gardner, Ingrid S. SketrisABSTRACT
PurposeDespite well-established concerns regarding adverse drug effects, antipsychotics are frequently prescribed for older adults. Our first objective was to identify trends in antipsychotic dispensations to older Nova Scotians. STOPP (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions) criteria identify antipsychotic use in those with a history of falls as potentially inappropriate. Our second objective was to iden...
Source: Current Therapeutic Research - September 20, 2018 Category: Drugs & Pharmacology Source Type: research
Antipsychotic dispensations in older adults, including continuation after a fall-related hospitalization: Identifying adherence to STOPP criteria using the Nova Scotia Seniors' Pharmacare and Canadian Institute for Health's Discharge Databases
Publication date: Available online 31 August 2018Source: Current Therapeutic ResearchAuthor(s): Shanna C. Trenaman, Barbara J. Hill-Taylor, Kara J. Matheson, David M. Gardner, Ingrid S. Sketris (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - September 1, 2018 Category: Drugs & Pharmacology Source Type: research
Coagulation factor plasma levels following administration of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients
Publication date: Available online 25 August 2018Source: Current Therapeutic ResearchAuthor(s): Masahiro Yasaka, Andres Brainsky, Peijin Zhang, Shigeki KushimotoAbstractPurposeFour-factor prothrombin complex concentrates (4F-PCCs) have been approved for urgent vitamin K antagonist (VKA) reversal in Western countries for many years. Ethnicity and genetic variations between populations may influence the pharmacokinetic profile of treatments and here we report plasma levels of vitamin K-dependent coagulation factors and proteins C and S in Japanese patients following administration of a 4F-PCC approved recently in Japan.Metho...
Source: Current Therapeutic Research - August 25, 2018 Category: Drugs & Pharmacology Source Type: research
Mono-injection intra-articulaire d'acide hyaluronique dans la gonarthrose : Étude multicentrique prospective ouverte (ART-ONE 75) avec comparaison post hoc versus placebo
ConclusionLa présente étude suggère l'efficacité clinique d'une mono-injection IA de 3 mL de solution viscoélastique contenant 75 mg d'AH natif de haut poids moléculaire (> 2 MDa). (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - August 24, 2018 Category: Drugs & Pharmacology Source Type: research
Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis
ConclusionsAlthough these results suggest that control of inflammation could have a beneficial effect on the lipid profile through an increase in HDL cholesterol levels, the observed protective effect on cardiovascular disease events by tumor necrosis factor blockers is likely to be explained by other mechanisms than changes in lipid levels or short-term effects on atherosclerosis of the carotid artery. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - August 15, 2018 Category: Drugs & Pharmacology Source Type: research
Mono-injection intra-articulaire d'acide hyaluronique dans la gonarthrose: Étude multicentrique prospective ouverte (ART-ONE 75) avec comparaison post hoc versus placebo
ConclusionLa présente étude suggère l'efficacité clinique d'une mono-injection IA de 3 mL de solution viscoélastique contenant 75 mg d'AH natif de haut poids moléculaire (> 2 MDa). (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - August 1, 2018 Category: Drugs & Pharmacology Source Type: research
Effects of Treatment with Adalimumab on Blood Lipids and Atherosclerosis in Patients with Rheumatoid Arthritis
ConclusionsAlthough these results suggest that control of inflammation could have a beneficial effect on the lipid profile through an increase in HDL, the observed protective effect on CVD events by TNF blockers is likely to be explained by other mechanisms than changes in lipid levels or short term effects on atherosclerosis of the carotid artery.ClinicalTrials.govIdentifierNCT01270087 (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - July 23, 2018 Category: Drugs & Pharmacology Source Type: research
Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or an Olmesartan/Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China
ConclusionsThe combination therapy with OLM or OLM/HCTZ was well tolerated. The total incidence of adverse events was 42.9% (n = 176). Most of the adverse events were mild in severity (39.5%; n = 162) and not associated with the drugs (33.2%). In conclusion, combination therapy with AML, OLM, or OLM/HCTZ can significantly lower BP safely and achieve a high BP control rate in patients with mild-to-moderate hypertension in China. ClinicalTrial.org identifier: ChiCTR-ONC-12001963. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - July 10, 2018 Category: Drugs & Pharmacology Source Type: research
